Lilly Asia Ventures has returned to back the immuno-oncology therapy developer’s latest round, eight months after participating in the company’s series B.

Asahi Kasei, GlaxoSmithKline and Johnson & Johnson helped the respiratory disease drug developer boost its overall funding to $150m.

IP Group has participated in a $92m series C round for Pulmocide, a developer of treatments for respiratory diseases that was spun out of Imperial College London.

GV has returned to back the indoor farming operator’s series C round at a $2.3bn valuation, helping to take its total funding to over $470m.

Exor-backed card issuing technology provider Lithic raised $43m while Mitsui Sumitomo Insurance is providing $36m to lead Upstream Security's series C round.

BioTheryX, Immuta and Pitch are among the companies that have raised fresh capital from corporates such as Intel Capital, Slack Fund, Citi Ventures and Dell Technologies Capital.

Slack-backed Loom has completed a $130m series C round led by Andreessen Horowitz.

Axa Venture Partners has helped put $60m into Virtuo, while Super collected $50m and Salto picked up $42m.

Asapp has doubled its valuation to $1.6bn in the space of a year, thanks to a $120m series C round backed by returning investor Telstra Ventures.

Novo Holdings has invested in the immuno-oncology drug developer which already counts 3SBio Group and Eisai as existing backers.